150
Participants
Start Date
September 30, 2004
Study Completion Date
August 31, 2007
rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
rMVA 10\^7 pfu /2mL administered in each deltoid
rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
Empty TBC-FPV
Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
rMVA 10\^8 pfu /2mL administered in each deltoid
rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
rMVA 10\^9 pfu /2mL administered in each deltoid
TBC-MVA and TBC-FPV
Empty MVA 10\^7 pfu/2mL administered into each deltoid
TBC-MVA and TBC-FPV
Empty MVA 10\^8 pfu/2mL administered into each deltoid
TBC-MVA and TBC-FPV
Empty MVA 10\^9 pfu/2mL administered into each deltoid
Univ. of Rochester HVTN CRS, Rochester
FHCRC/UW Vaccine CRS, Seattle
Alabama Vaccine CRS, Birmingham
Saint Louis Univ. School of Medicine, HVTU, St Louis
Projeto Praça Onze/Hesfa Crs, Rio de Janeiro
Sao Paulo HVTU - CRT DST/AIDS CRS, São Paulo
National Institute of Allergy and Infectious Diseases (NIAID)
NIH